Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 study to assess adverse events, changes in disease activity, and pharmacokinetics of intravenous ABBV901 given alone or with Bevacizumab in adults with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ABBV901
• Bevacizumab (bevacizumab)

Snippet

Sponsor: AbbVie | Conditions: Ovarian Cancer | Phase 1 | Status: RECRUITING